Compare NTRA & AER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTRA | AER |
|---|---|---|
| Founded | 2003 | 1995 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Diversified Commercial Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.0B | 23.1B |
| IPO Year | 2015 | 2006 |
| Metric | NTRA | AER |
|---|---|---|
| Price | $244.06 | $139.70 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 6 |
| Target Price | ★ $227.69 | $144.17 |
| AVG Volume (30 Days) | ★ 1.7M | 1.4M |
| Earning Date | 11-06-2025 | 10-29-2025 |
| Dividend Yield | N/A | ★ 0.77% |
| EPS Growth | N/A | ★ 63.90 |
| EPS | N/A | ★ 20.89 |
| Revenue | $2,116,676,000.00 | ★ $8,344,637,000.00 |
| Revenue This Year | $32.77 | $4.58 |
| Revenue Next Year | $16.51 | N/A |
| P/E Ratio | ★ N/A | $6.70 |
| Revenue Growth | ★ 38.17 | 6.67 |
| 52 Week Low | $125.38 | $85.57 |
| 52 Week High | $245.59 | $140.73 |
| Indicator | NTRA | AER |
|---|---|---|
| Relative Strength Index (RSI) | 80.03 | 69.31 |
| Support Level | $233.67 | $131.62 |
| Resistance Level | $240.18 | $134.04 |
| Average True Range (ATR) | 7.39 | 2.66 |
| MACD | 0.68 | 0.38 |
| Stochastic Oscillator | 97.49 | 92.05 |
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
AerCap Holdings NV is an aircraft leasing company. Its activities include leasing, financing, sales, and management of commercial aircraft and engines. It also provides aircraft asset management and corporate services to securitization vehicles, joint ventures, and other third parties.It has one business segment: leasing, financing, sales and management of commercial flight equipment (Commercial Flight Equipment Segment).Through its subsidiary, the group also provides engine leasing, certified aircraft engines, airframes, and engine parts. Its geographical segments include United Kingdom, United States, and Other countries.